Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forticell Bioscience Inc.

Latest From Forticell Bioscience Inc.

Start-Ups Move Stem Cell Products Forward On Long Path To Market

The dream of turning stem cell research into mainstream clinical therapies is making significant progress, as a large number of cell-based clinical studies are currently underway - some 2,700 stem cell clinical trials registered with between February 2000 and June 2010. While several companies have launched stem cell products onto the market, it’s the number of products in the pipeline that is starting to capture the attention of observers – including investors – who believe activity in current clinical trials is a telling sign of where the industry is headed.

BioPharmaceutical Medical Device

Salve for the Wound Care Market

Wound care, once known as an investment graveyard, is changing. An advanced wound care market that once focused high-end technology on the small and difficult market of burns has now recognized an opportunity in chronic wounds, an enormous and growing market driven by the demographics of aging, and that segment has recently witnessed a dramatic success story. In 2004, the most successful medical device IPO was that of wound care company Kinetic Concepts.
Medical Device Platform Technologies

Renovo Ltd.

There are currently no effective pharmacological treatments to prevent scarring following trauma or surgery. Renovo, a spin-off from the University of Manchester, was set up two years ago with this market in mind. Renovo has two anti-scarring compounds in clinical trials, based on Transforming Growth Factor Beta 3, which appears to promote healing without scarring in embryos, and an antagonist of Transforming Growth Factor Beta 1 and Beta 2, growth factors which appear to be associated with scarring in adults.

Wound Healing Regenerates, Slowly

Wound healing has long been a business of tape and gauze, not biotech. But now two tissue-engineered skin replacements and a growth factor have reached the market’s doorstep. Are these lucrative new product categories or not?
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ortec International Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Forticell Bioscience Inc.
  • Senior Management
  • Costa Papastephanou, PhD, CEO
    Alan Schoenbart, CFO
    Mel Silberklang, CSO & VP, R&D
    Alain Klapholz, Dir., Strategy & Planning
  • Contact Info
  • Forticell Bioscience Inc.
    Phone: (212) 740-6999
    3960 Broadway
    New York, NY 10032